MEDIPATH FRANCE in the news

MEDIPATH sent 200,000 examination results to the National Cancer Registry to enhance cancer surveillance and research in France.

Medipath's Limoges laboratory, specializing in tissue and cell analysis for diagnostics, has experienced a 21% increase in treated cases since 2023 due to prevention campaigns and uses AI.

Medipath is implementing Ibex's AI tool Galen TM Prostate across its centers to enhance prostate cancer diagnosis accuracy and quality control.

Medipath appoints Franck Baretti as deputy CEO to support its growth, consolidation, and international expansion plans.

MEDIPATH, a leading French cancer diagnostic group, appointed Franck Baretti as Deputy CEO to drive growth, digital innovation, and international expansion.

MEDIPATH is enhancing its pathology lab automation with Sakura's Tissue-Tek AutoTEC ® a120 embedder to boost productivity and diagnostic accuracy.

MEDIPATH enhanced cancer diagnostics in France by implementing automated embedding systems from Sakura Finetek to improve sample traceability, workflow, and diagnostic quality.

VitaDX secured extacutec6.5 million to advance its early cancer detection technology, aiming for market expansion in Europe and the US, and developing new diagnostic solutions for bladder and thyroid cancers.

Medipath uses Philips digital pathology and AI to speed up and improve diagnostic accuracy across its network, enhancing patient care.

MEDIPATH is opening its pathology labs to the public across France to showcase its medical expertise and the integration of Artificial Intelligence in cancer diagnostics.

Medipath's Limoges pathology center is opening to the public to raise awareness about its key role in early cancer detection and diagnosis.

MEDIPATH Perpignan will open its pathology center to the public on June 13, highlighting cancer screening, AI use, and expert diagnostics.

Medipath is hosting an open day in Bordeaux to showcase the role of anatomical pathology and AI in early cancer detection and screening.

MEDIPATH Montpellier is hosting a public open house on June 12, 2024, showcasing its cancer screening pathology center, advanced diagnostics, and AI integration.

Medipath is hosting open-house events across France to demonstrate its cancer diagnostic expertise and use of AI technology in pathology.

Médipath secured significant public funding under France 2030 for AI-driven cancer diagnostic tools, reinforcing its role as an independent leader in medical pathology in France.

MEDIPATH, a pathology diagnosis company, won France 2030 awards for AI-driven medical imaging projects improving cancer diagnostics.

Medipath, a French medical pathology firm, won two France 2030 awards for AI-driven cancer detection projects and processes 10% of national cancer diagnoses with 700 employees.

MEDIPATH, a pathology-focused medical company, won France 2030 funding for AI-driven diagnostic imaging projects targeting cervical and thyroid cancer.

Medipath is France's leading anatomical pathology group, innovating in cancer diagnostics with AI and molecular techniques, expanding regionally and internationally while maintaining rapid, local service.